BrightGene chairman proposes share buyback for employee incentives

On September 25, 2025, BrightGene Bio-Medical Technology (Suzhou) Co., Ltd. announced a proposal from its controlling shareholder, actual controller, and chairman, Yuan Jiandong, for a share repurchase. The proposed buyback, utilizing company-owned funds through concentrated bidding, is intended for equity incentives or employee stock ownership plans. Any unutilized repurchased shares within three years of implementation will be cancelled.

The proposal suggests a buyback price not exceeding 150% of the average stock trading price over the 30 trading days prior to the board's approval. The total amount for the repurchase is set to be no less than RMB 10 million and not exceeding RMB 20 million, funded entirely by the company’s own capital. The buyback period will be within 12 months from the date the board approves the plan.

Yuan Jiandong confirmed no prior share transactions within six months of the proposal and stated no current plans for changes in holdings during the repurchase period. He pledged to support the proposal at the board meeting. The company has cautioned that the plan is subject to necessary approval procedures and carries inherent uncertainties.